Free tool
FAERS Monitor: Imjudo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761289 or its brand name (Imjudo, Tremelimumab-Actl). Reports on generic versions are filed under their own applications.
Reports
4,428
Serious
4,294
97% of reports
Hospitalization
2,118
Death reported
1,275
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death412
- diarrhoea301
- malignant neoplasm progression294
- pyrexia228
- colitis194
- cytokine release syndrome175
- immune-mediated enterocolitis159
- rash151
- liver disorder133
- pneumonia124
- pneumonitis103
- myocarditis100
- hepatic function abnormal97
- immune-mediated hepatic disorder97
- adrenal insufficiency93
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 3 |
| 2008 | 6 |
| 2009 | 2 |
| 2012 | 1 |
| 2014 | 4 |
| 2015 | 7 |
| 2016 | 40 |
| 2017 | 409 |
| 2018 | 405 |
| 2019 | 86 |
| 2020 | 106 |
| 2021 | 87 |
| 2022 | 76 |
| 2023 | 516 |
| 2024 | 966 |
| 2025 | 966 |
| 2026 | 748 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,731 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| immune-mediated hepatic disorderSignal | 97 | 248.6 | 203.1 | 22,497 |
| immune-mediated enterocolitisSignal | 159 | 214.6 | 183.6 | 32,147 |
| myocarditisSignal | 100 | 41.8 | 34.4 | 3,909 |
| cytokine release syndromeSignal | 175 | 41.8 | 36.1 | 6,874 |
| adrenal insufficiencySignal | 93 | 36.7 | 30.0 | 3,169 |
| colitisSignal | 194 | 24.4 | 21.3 | 4,321 |
| pneumonitisSignal | 103 | 18.0 | 14.9 | 1,636 |
| liver disorderSignal | 133 | 14.3 | 12.1 | 1,629 |
| malignant neoplasm progressionSignal | 294 | 13.7 | 12.2 | 3,448 |
| hepatic function abnormalSignal | 97 | 12.4 | 10.2 | 1,002 |
| pyrexiaSignal | 228 | 3.1 | 2.8 | 334 |
| deathSignal | 412 | 2.3 | 2.1 | 305 |
| diarrhoeaSignal | 301 | 2.2 | 2.0 | 206 |
| pneumonia | 124 | 1.8 | 1.5 | 46 |
| rash | 151 | 1.6 | 1.4 | 38 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.